Impact of synthetic surfactant CHF5633 with SP-B and SP-C analogues on lung function and inflammation in rabbit model of acute respiratory distress syndrome

Abstract

Acute respiratory distress syndrome (ARDS) is associated with diffuse inflammation, alveolar epithelial damage, and leakage of plasma proteins into the alveolar space, which together contribute to inactivation of pulmonary surfactant and respiratory failure. Exogenous surfactant delivery is therefore considered to hold potential for ARDS treatment, but clinical trials with natural derived surfactant or synthetic surfactant containing a surfactant protein C (SP-C) analogue have been negative. Synthetic surfactant CHF5633, containing analogues of SP-B and SP-C, may be effective against ARDS. The aim here was to compare treatment effects of CHF5633 and animal-derived surfactant poractant alfa in animal model of ARDS. ARDS was induced in adult New Zealand rabbits by mild lung lavages followed by injurious ventilation until respiratory failure (P/F ratio

Keywords

ARDS model; CHF5633; inflammation; lung function; synthetic pulmonary surfactant

Published in

Physiological Reports
2021, volume: 9, number: 1, article number: e14700
Publisher: WILEY

SLU Authors

• Rising, Anna

  • Department of Animal Biosciences, Swedish University of Agricultural Sciences
    
  • Karolinska Institutet

Associated SLU-program

Translational and comparative medicine

UKÄ Subject classification

Physiology and Anatomy

Publication identifier

• DOI: https://doi.org/10.14814/phy2.14700

Permanent link to this page (URI)

https://res.slu.se/id/publ/118681